EndeavourRx

Akili is a digital medicine company specializing in the development of cognitive treatments delivered through immersive video game experiences. The company's flagship product, EndeavourRx, is the first FDA-cleared prescription digital therapeutic designed to improve attention function in children with ADHD. Utilizing its proprietary Selective Stimulus Management Engine (SSME) technology, Akili targets specific neural networks in the prefrontal cortex to enhance cognitive control. Beyond pediatric ADHD, the company has expanded its portfolio to include over-the-counter digital treatments for adults and is investigating applications for multiple sclerosis and depression. In 2024, Akili was acquired by Virtual Therapeutics to integrate its clinically validated digital health solutions into a broader mental health platform.